Skip to main content

Table 3 Rate of response after 3 and 5 months, n (%)

From: Omalizumab for chronic urticaria in Latin America

Time (months) No. of patients Complete response Partial response Non-response
3 9 3 (33.3) 4 (44.4) 2 (22.2)
5 4 3 (75.0) 0 (0.0) 1 (25.0)